HOME > TOP STORIES

TOP STORIES

REGULATORY CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris

November 17, 2011
REGULATORY High Court Turns Down Iressa Compensation Appeal

November 16, 2011
REGULATORY 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC

November 16, 2011
BUSINESS Japan’s Jul-Sep 2011 Ethical Drug Market Grows 7.7%: IMS Japan

November 15, 2011
BUSINESS Otsuka Forms Alliance with Lundbeck in CNS Field

November 14, 2011
BUSINESS Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before

November 11, 2011
REGULATORY MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems

November 10, 2011
REGULATORY Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA

November 10, 2011
BUSINESS Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September

November 9, 2011
BUSINESS Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD

November 9, 2011
BUSINESS Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets

November 9, 2011
BUSINESS Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”

November 8, 2011
BUSINESS Suzuken President Ota Says Wholesale Business Recovery Crucial

November 8, 2011
BUSINESS 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales

November 7, 2011
REGULATORY CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing

November 4, 2011
BUSINESS Eisai President Says Japan, China to Become Key Battlefields for Aricept

November 2, 2011
BUSINESS Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC

November 2, 2011
BUSINESS DSP to Boost Domestic CNS Business for Early Maximization of Lonasen

November 1, 2011
BUSINESS Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept

November 1, 2011
BUSINESS DSP: Strong Yen Contributes to 5.6% Decline in Sales

November 1, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…